AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge

AnaptysBio announced positive results from its Phase 2b RENOIR trial evaluating rosnilimab for rheumatoid arthritis treatment2 3 6.

The trial met its primary endpoint, showing statistically significant improvement in DAS28-CRP scores across all rosnilimab doses compared to placebo at Week 122 6.

Rosnilimab demonstrated the highest ever reported Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) responses over a six-month period2 3.

69% of rosnilimab-treated patients achieved CDAI LDA at Week 14, with sustained and potentially deepening responses observed at Week 282 6.

The drug showed a favorable safety profile, with adverse event rates similar to placebo2 6.

AnaptysBio's stock surged over 60% following the announcement of the trial results2.

Analysts from various firms, including H.C. Wainwright and Wedbush, have raised their price targets for AnaptysBio stock4 7.

The company plans to report complete Week 28 data and additional translational data in Q2 2025, as well as top-line Week 12 Phase 2 data for rosnilimab in ulcerative colitis in Q4 20252 6.